Nika Pharmaceuticals Files 8-K on Asset Deal & Bylaw Changes
Ticker: NIKA · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1145604
| Field | Detail |
|---|---|
| Company | Nika Pharmaceuticals, Inc (NIKA) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, bylaws, corporate-action
TL;DR
NIKA filed an 8-K for asset deal completion & bylaw changes. Formerly Centennial Growth.
AI Summary
Nika Pharmaceuticals, Inc. filed an 8-K on March 5, 2024, reporting on events that occurred on March 1, 2024. The filing indicates a completion of acquisition or disposition of assets, amendments to articles of incorporation or bylaws, and the filing of financial statements and exhibits. The company was formerly known as Centennial Growth Equities Inc. and changed its name on July 24, 2001.
Why It Matters
This 8-K filing signals significant corporate actions, including asset transactions and potential changes to the company's governance, which could impact its operational structure and future strategy.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate actions like asset acquisitions/dispositions and bylaw amendments, which can introduce operational and strategic risks.
Key Players & Entities
- NIKA PHARMACEUTICALS, INC. (company) — Registrant
- Centennial Growth Equities Inc. (company) — Former Company Name
- March 4, 2024 (date) — Date of Report
- March 1, 2024 (date) — Earliest Event Reported
- July 24, 2001 (date) — Date of Name Change
- 2269 Merrimack Valley Avenue (address) — Principal Executive Offices
- Henderson, NV 89044 (address) — Principal Executive Offices
- 702-326-3615 (phone_number) — Business Phone
FAQ
What specific assets were acquired or disposed of by Nika Pharmaceuticals, Inc. on March 1, 2024?
The filing indicates the completion of an acquisition or disposition of assets, but does not specify the exact assets involved in this 8-K.
What were the key amendments made to Nika Pharmaceuticals, Inc.'s articles of incorporation or bylaws?
The filing notes amendments to articles of incorporation or bylaws as an item of information, but the specific details of these amendments are not provided in this summary.
When did Nika Pharmaceuticals, Inc. officially change its name from Centennial Growth Equities Inc.?
Nika Pharmaceuticals, Inc. officially changed its name from Centennial Growth Equities Inc. on July 24, 2001.
What is the principal executive office address for Nika Pharmaceuticals, Inc.?
The principal executive office address for Nika Pharmaceuticals, Inc. is 2269 Merrimack Valley Avenue, Henderson, NV 89044.
What is the business phone number listed for Nika Pharmaceuticals, Inc.?
The business phone number listed for Nika Pharmaceuticals, Inc. is (702) 326-3615.
Filing Stats: 491 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-03-05 07:01:53
Filing Documents
- form8k.htm (8-K) — 20KB
- exhibit99-1.htm (EX-99.1 CHARTER) — 38KB
- image_001.jpg (GRAPHIC) — 38KB
- image_002.jpg (GRAPHIC) — 45KB
- image_007.jpg (GRAPHIC) — 25KB
- image_003.jpg (GRAPHIC) — 54KB
- image_006.jpg (GRAPHIC) — 29KB
- image_005.jpg (GRAPHIC) — 34KB
- 0001826466-24-000020.txt ( ) — 534KB
- nika-20240301.xsd (EX-101.SCH) — 3KB
- nika-20240301_lab.xml (EX-101.LAB) — 33KB
- nika-20240301_pre.xml (EX-101.PRE) — 22KB
- form8k_htm.xml (XML) — 3KB
.01 Completion of Acquisition or Disposition of Assets
Item 2 .01 Completion of Acquisition or Disposition of Assets. Nika Pharmaceuticals, Inc. has gone through a market extension merger with Nika BioTechnology, Inc., effective as of March 1, 2024. The Agreement and Plan of Merger was approved by the shareholders and board of directors of both companies on February 12, 2024. Pursuant to the terms of the merger, Nika BioTechnology, Inc. will merge into Nika Pharmaceuticals, Inc. for which the shareholders of Nika BioTechnology, Inc. will receive, as consideration, one (1) share of NKPH common stock for each share of NIKA common stock that they own. Both entities have the same board of directors and officers who will continue to remain in the same roles in the consolidated entity. Dimitar Slavchev Savov owns approximately 69% of the common stock and 100% of the Preferred A stock of Nika BioTechnology, Inc, as well as approximately 37% of the common stock and 100% of the Preferred A stock of Nika Pharmaceuticals, Inc. Section 5 – Corporate Governance and Management
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Pursuant to the terms of the Agreement and Plan of Merger and the approval of the company's board of directors and shareholders, Nika Pharmaceuticals, Inc. has filed an Amendment to the Articles of Incorporation to increase the number of authorized Preferred A stock from 10,000,000 to 15,000,000, effective as of March 4, 2024 when the amendment was filed with the Colorado Secretary of State.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Nika Pharmaceuticals, Inc. Form 425
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized. NIKA PHARMACEUTICALS, INC. Dated: March 4, 2024 By: /s/ Dimitar Slavchev Savov Dimitar Slavchev Savov Chief Executive Officer, Director